{"altmetric_id":5105661,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Eli Lilly and Company"],"first_seen_on":"2016-02-08T04:06:49+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1384272129,"links":["http:\/\/clinicaltrials.gov\/show\/NCT01285037"],"nct_id":"NCT01285037","pubdate":"2011-01-26T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"A Study of LY2801653 in Advanced Cancer","type":"clinical_trial_study_record"},"altmetric_score":{"score":2,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":2},"context_for_score":{"all":{"total_number_of_other_articles":8029085,"mean":6.8046097213542,"rank":3437514,"this_scored_higher_than_pct":55,"this_scored_higher_than":4477342,"rank_type":"exact","sample_size":8029085,"percentile":55},"similar_age_3m":{"total_number_of_other_articles":332236,"mean":9.7225432901408,"rank":127798,"this_scored_higher_than_pct":59,"this_scored_higher_than":198078,"rank_type":"exact","sample_size":332236,"percentile":59},"this_journal":{"total_number_of_other_articles":22412,"mean":10.439438490027,"rank":9008,"this_scored_higher_than_pct":58,"this_scored_higher_than":13127,"rank_type":"exact","sample_size":22412,"percentile":58},"similar_age_this_journal_3m":{"total_number_of_other_articles":965,"mean":15.008562240664,"rank":368,"this_scored_higher_than_pct":61,"this_scored_higher_than":590,"rank_type":"exact","sample_size":965,"percentile":61}}},"demographics":[],"counts":{"total":{"posts_count":2},"googleplus":{"unique_users_count":2,"unique_users":["Ana Corrionero","enzymlogic"],"posts_count":2}},"posts":{"googleplus":[{"title":"Multi-kinase and long-lasting LY2801653 inhibitor displays promising anti-tumor activities MET over...","url":"https:\/\/plus.google.com\/105816743836234537232\/posts\/FM3YmfiZKWa","citation_ids":[1900889,5105661],"posted_on":"2013-11-12T16:02:09+00:00","summary":"Multi-kinase and long-lasting LY2801653 inhibitor displays promising anti-tumor activities MET over... Multi-kinase and long-lasting LY2801653 inhibitor displays promising anti-tumor activities\u00a0MET over-expression, aberrant autocrine or paracrine ligand pr","author":{"name":"Ana Corrionero","url":"https:\/\/plus.google.com\/105816743836234537232","image":"https:\/\/lh6.googleusercontent.com\/-cDgnNyGABc4\/AAAAAAAAAAI\/AAAAAAAAAKU\/mUoG6dNpm5k\/photo.jpg?sz=50","id_on_source":"105816743836234537232"}},{"title":"Multi-kinase and long-lasting LY2801653 inhibitor displays promising anti-tumor activities MET over...","url":"https:\/\/plus.google.com\/101717105109680779896\/posts\/RT4HibLMLET","citation_ids":[1900889,5105661],"posted_on":"2013-11-10T19:44:41+00:00","summary":"Multi-kinase and long-lasting LY2801653 inhibitor displays promising anti-tumor activities MET over... Multi-kinase and long-lasting LY2801653 inhibitor displays promising anti-tumor activities\u00a0MET over-expression, aberrant autocrine or paracrine ligand pr","author":{"name":"enzymlogic","url":"https:\/\/plus.google.com\/+Enzymlogic","image":"https:\/\/lh3.googleusercontent.com\/-06-ubUYVrkE\/AAAAAAAAAAI\/AAAAAAAAAqk\/2MDJINwZzyQ\/photo.jpg?sz=50","id_on_source":"101717105109680779896"}}]}}